A phase II trial of pemetrexed (P), gemcitabine (G), and bevacizumab (BV) in untreated patients (pts) with advanced non-small cell lung cancer (NSCLC).
A. Wozniak,G. Kalemkerian,S. Gadgeel,B. Schneider,M. Valdivieso,R. Venkatramanamoorthy,D. Hackstock,W. Chen,L. Heilbrun,J. Ruckdeschel
DOI: https://doi.org/10.1200/jco.2009.27.15_suppl.e19099
IF: 45.3
2016-09-22
Journal of Clinical Oncology
Abstract:e19099 Background: P and G are active agents with acceptable toxicity profiles in the treatment of NSCLC. The addition of BV to chemotherapy has resulted in a significant improvement in survival for pts with non-squamous NSCLC. We are currently conducting a phase II trial of P, G and BV on a novel every two week schedule in untreated pts with advanced NSCLC.
METHODS
Advanced, non-squamous NSCLC pts with measurable/evaluable disease, no prior treatment for advanced disease, PS 0-1, adequate hepatic, renal and bone marrow function, treated brain metastases were eligible. No unstable hypertension/cardiac disease/vascular disease, hemoptysis, anti-coagulation, recent major surgery, no cavitation or close proximity of primary cancer to a major vessel were allowed. Pts received P 500 mg/m2, G 1,500 mg/m2, and BV 10 mg/kg every 2 weeks for 12 cycles. Doses were reduced to P 400 mg/m2 and G 1,200 mg/m2 when grade 4 neutropenia occurred in the first 2 patients. BV was continued until disease progression or toxicity. Planned accrual is 42 patients. Primary endpoint is progression-free survival. Secondary endpoints are response rate (RR), toxicity, time to progression and overall survival.
RESULTS
20 pts have been accrued. Median age 57.5 yrs, males-55%, stage IV 90%, adenocarcinoma 75%. 18 pts are response evaluable (2 were too early to assess). 11/18 (61%) pts had a response (1 CR, 7 PR, 3 unconfirmed PR) (90% CI for RR is 0.42 - 0.77), and 3 had SD ( 17%) for a disease control rate of 78%. Currently the median treatment cycles for all pts are 6 (range 1-12). All pts are evaluable for toxicity. Grade 3- 4 toxicities: neutropenia 4, anemia 1, thrombocytopenia 2, lymphopenia 1, febrile neutropenia 1, fatigue 4, hypertension 1, GI 2, ALT/AST 3, pneumonitis 1, muscular weakness 1, metabolic 2, otitis media 1.
CONCLUSIONS
The combination of P, G, and BV is a very active and tolerable treatment for NSCLC despite the preliminary nature of these results. Updated information will be presented at the meeting. This research is supported by Lilly Oncology and Genentech. [Table: see text].